Education
About Us
Working with TipRanks
Follow Us
Vivani Medical (VANI)
NASDAQ:VANI
VANI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $2.22
Previous CloseN/A
Volume36.09K
Average Volume (3M)88.60K
Market Cap
$65.75M
Enterprise Value$65.05M
Total Cash (Recent Filing)$3.18M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 19, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding59,234,688
10 Day Avg. Volume112,314
30 Day Avg. Volume88,601
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-182.22
Enterprise Value/Ebitda-2.71
Forecast
1Y Price Target
$6.00Price Target Upside440.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first subject has been implanted with NPM-115 in the Phase 1 LIBERATE-1 study, and the procedure was successful with no unexpected adverse events.
Market OpportunitiesThe GLP-1 and obesity treatment market continues to grow, which can accommodate multiple players, enhancing opportunities for Vivani.
Regulatory ProgressVivani received regulatory approval in Australia to initiate the first-in-human clinical trial of NPM-115.
Bears Say
Financial PerformanceNet loss totaled $6.0M in 3Q24, with cash flows from operating activities being negative $5.7M.
Risks And ChallengesRisks include failure of NPM-115 in clinical trials, failure to secure regulatory approval, and failure to achieve commercial success due to market size, penetration rate, and competition.
---
Ownership Overview
37.87% Insiders
2.17% Mutual Funds
4.86% Other Institutional Investors
53.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $1.03 and its highest was $2.22 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $65.75M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is May 19, 2025 which is in 50 days.
How were Vivani Medical’s earnings last quarter?
Currently, no data Available
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.1.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 59,234,688 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
---
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (440.54% Upside)
$6.00 (440.54% Upside)
Insider Transactions
Bought Shares
Worth $1.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.00%
12-Months-Change
Fundamentals
Return on Equity
-105.35%
Trailing 12-Months
Asset Growth
-19.55%
Trailing 12-Months
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
---
VANI Stock 12 Month Forecast
Average Price Target
$6.00
▲(440.54% Upside)
Technical Analysis
Best Analysts Covering VANI
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-8.68%
reiterated a buy rating 17 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -8.68% per trade.
---